Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Ado-Trastuzumab Emtansine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Salivary Gland Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Hemangiosarcoma 1 HER2-positive Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1 Adenocarcinoma Of Esophagus 1

Interventions

tucatinib 1 Fulvestrant 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06595563 2026-02-19

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡